Arkolith/Insider Trading/MBX/Form 4

Azoulay Salomon

Chief Medical OfficerMBX Biosciences, Inc. (MBX) · full profile →Form 4 · filed May 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.7M
Net Open-Market Flow
-$2.7M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 8, 2026Option exercise(M)55K$10.46$575K70K
May 8, 2026Sell(S)55K$38.38$2.1M15K
May 8, 2026Option exercise(M)15K$16.00$240K30K
May 8, 2026Sell(S)15K$38.30$575K15K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 8, 2026Option exercise(M)55K—$0195K
May 8, 2026Option exercise(M)15K—$030K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-216704) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML